Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Treatment for Ulcerative Colitis: Supporting Gut Healing and Symptom Control
Transcript
- 0:00SPEAKER_01: Imagine your body producing like a military force that is so aggressive, um, so relentlessly hyperactive that it essentially just scorches the earth of your own internal organs.
- 0:14SPEAKER_00: Right.
- 0:14SPEAKER_00: A totally uncontrolled response.
- 0:16SPEAKER_01: It exactly.
- 0:16SPEAKER_01: You're trying to rebuild the infrastructure, but this internal army is just burning everything down as fast as you can lay the groundwork.
- 0:22SPEAKER_00: It's a brutal cycle.
- 0:23SPEAKER_01: It really is.
- 0:24SPEAKER_01: And that vivid, incredibly frustrating reality is well, it's what everyday life looks like for anyone living with ulcerative colitis.
- 0:33SPEAKER_01: So welcome to today's deep dive.
- 0:35SPEAKER_00: Glad to be here for this one.
- 0:36SPEAKER_00: It's an important topic.
- 0:37SPEAKER_01: Definitely.
- 0:38SPEAKER_01: Today, our mission is to unpack this really fascinating stack of informational and clinical materials we've received from Sarona Cell.
- 0:45SPEAKER_00: Yeah, they're a doctor-led regenerative medicine center.
- 0:47SPEAKER_01: Aaron Powell Right.
- 0:48SPEAKER_01: And we are exploring the uh rapidly evolving world of stem cell therapy, specifically how it's being deployed to tackle this notoriously difficult autoimmune condition.
- 0:58SPEAKER_00: Aaron Powell You know, the landscape of stem cell therapy has historically been fraught with just a lot of noise.
- 1:03SPEAKER_01: Oh, for sure.
- 1:04SPEAKER_01: So much noise.
- 1:05SPEAKER_00: Right.
- 1:05SPEAKER_00: For a long time, the messaging available to the public felt a bit like the Wild West, just characterized by um these bold claims and really very little verifiable science.
- 1:17SPEAKER_01: Aaron Powell Basically just marketing hype.
- 1:19SPEAKER_00: Exactly.
- 1:19SPEAKER_00: Yeah.
- 1:19SPEAKER_00: But the clinical sources we're analyzing today, they offer a look at a completely different paradigm.
- 1:25SPEAKER_00: We're looking at a highly structured, highly regulated, and medically supervised approach.
- 1:30SPEAKER_01: Which is so refreshing to see.
- 1:32SPEAKER_00: It is.
- 1:32SPEAKER_00: It's moving this science out of the realm of, you know, sketchy medical tourism and into rigorous clinical application.
- 1:39SPEAKER_01: Aaron Powell And whether you're dealing with an autoimmune issue yourself or you're just insanely curious about the absolute cutting edge of regenerative medicine, this deep dive is going to separate that biological science from the marketing hype.
- 1:51SPEAKER_00: Let's get into it.
- 1:52SPEAKER_01: Okay, let's unpack this.
- 1:53SPEAKER_01: So before we can really understand how stem cells act as a treatment, we have to look at the battlefield, right?
- 1:58SPEAKER_00: Yeah, the environment they're entering.
- 1:59SPEAKER_01: Exactly.
- 2:00SPEAKER_01: We need to understand the specific biological problem they are actually trying to solve in the gut.
- 2:05SPEAKER_01: So what is physically happening inside someone with ulcerative colitis?
- 2:09SPEAKER_00: Well, the primary battlefield is the inner lining of the large intestine, specifically the colon and the rectum.
- 2:15SPEAKER_01: Okay.
- 2:16SPEAKER_00: Ucerative colitis, or UC, is a chronic inflammatory condition.
- 2:21SPEAKER_00: To understand the mechanism, you really have to look at the immune system's basic function.
- 2:26SPEAKER_01: Which is to protect you, obviously.
- 2:27SPEAKER_00: Right.
- 2:28SPEAKER_00: When it detects a threat, it triggers inflammation to fight off that threat.
- 2:32SPEAKER_00: Yeah.
- 2:32SPEAKER_00: But in a UC patient, the immune system gets basically switched on.
- 2:36SPEAKER_01: And it just stays on.
- 2:37SPEAKER_00: Exactly.
- 2:38SPEAKER_00: For reasons researchers are um still working to fully map out, it just refuses to switch off.
- 2:43SPEAKER_00: It fuels this relentless localized immune response right there in the mucosal lining of the gut.
- 2:50SPEAKER_01: Which means the surface of the colon becomes perpetually inflamed, right?
- 2:53SPEAKER_01: Like fragile and prone to developing open sores or ulcers.
- 2:57SPEAKER_00: Yeah, it's severely damaging.
- 2:59SPEAKER_01: And looking at the clinical descriptions in our sources, I mean, it causes severe bleeding, chronic pain, this unpredictable urgency to use the bathroom, it's a massive decruption to a person's life.
- 3:10SPEAKER_00: It's completely debilitating.
- 3:11SPEAKER_01: We aren't talking about a mild stomach ache here.
- 3:14SPEAKER_01: This is a condition that dictates, you know, what you can eat, whether you can sit through a work meeting, how you sleep.
- 3:19SPEAKER_00: It is entirely debilitating for many patients.
- 3:22SPEAKER_00: Now, the standard medical treatments, which typically involve a ladder of medications.
- 3:27SPEAKER_01: Like what?
- 3:27SPEAKER_00: Well, ranging from five ASAs to powerful immunosuppressants or biologics, those are the necessary first line of defense.
- 3:35SPEAKER_00: But they have significant limitations.
- 3:38SPEAKER_01: Right.
- 3:39SPEAKER_00: For a certain percentage of patients, these medications just fail completely.
- 3:42SPEAKER_01: Wow.
- 3:43SPEAKER_00: Yeah.
- 3:43SPEAKER_00: And for others, they might work for a while but eventually lose efficacy, or the patient develops intolerable side effects.
- 3:49SPEAKER_00: Trevor Burrus, Jr.
- 3:50SPEAKER_01: Which then leads to what?
- 3:51SPEAKER_01: Steroids?
- 3:52SPEAKER_00: Precisely.
- 3:53SPEAKER_01: Yeah.
- 3:54SPEAKER_00: That often leads to a heavy reliance on repeated courses of corticosteroids, which brings a whole host of severe long-term health risks.
- 4:02SPEAKER_01: Like bone density loss.
- 4:03SPEAKER_00: Bone density loss, increased infection rates, you name it.
- 4:06SPEAKER_01: Aaron Powell I have a hard time visualizing how those standard meds actually fix the root problem, though.
- 4:12SPEAKER_01: Like I keep thinking of the immune system in a UC patient, like a faulty, hypersensitive car alarm that just won't shut off.
- 4:19SPEAKER_00: Oh, that's a really good analogy.
- 4:21SPEAKER_01: Aaron Powell Right.
- 4:21SPEAKER_01: It's blaring constantly, it's draining the battery, completely destroying the piece of the neighborhood, which is the gut in this case.
- 4:28SPEAKER_00: Right, right.
- 4:29SPEAKER_01: It sounds like standard immunosuppressants are basically just throwing a heavy blanket over the car to muffle the siren.
- 4:36SPEAKER_01: Like you might not hear it as loudly, but the alarm system itself is still fundamentally broken.
- 4:41SPEAKER_00: Aaron Powell And we connect this to the bigger picture of gastroenterology.
- 4:45SPEAKER_00: That analogy highlights the exact limitation of conventional symptom management.
- 4:49SPEAKER_01: Because you're just muffling the sound.
- 4:51SPEAKER_00: Exactly.
- 4:52SPEAKER_00: Muffling the siren might give the patient a temporary reprieve, but the underlying dysfunction remains.
- 4:58SPEAKER_00: The ultimate medical goal in treating ulcerative colitis isn't just symptom masking.
- 5:04SPEAKER_01: Okay, what is it then?
- 5:05SPEAKER_00: It's a clinical endpoint called mucosal healing.
- 5:07SPEAKER_01: Mucosal healing.
- 5:08SPEAKER_01: Okay, break that down for me.
- 5:10SPEAKER_01: Does that just mean the patient fills out a questionnaire and says, hey, I feel better today?
- 5:13SPEAKER_00: No, no, it goes much deeper than subjective feeling.
- 5:17SPEAKER_00: Mucosal healing means that if a gastroenterologist goes in and looks at the colon with a scope, the tissue lining actually looks completely healthy and intact.
- 5:28SPEAKER_01: Wait, really?
- 5:29SPEAKER_01: Like the ulcers are gone.
- 5:30SPEAKER_00: Yes.
- 5:31SPEAKER_00: The ulcers have closed, the tissue has recovered its normal vascular pattern, and crucially, the inflammatory markers circulating in the blood have dropped back to baseline.
- 5:40SPEAKER_01: Oh wow, so it's measurable.
- 5:42SPEAKER_00: Highly measurable.
- 5:43SPEAKER_00: That is the holy grail of UC treatment.
- 5:45SPEAKER_00: Because achieving true mucosal healing drastically reduces the chance of future relapses.
- 5:51SPEAKER_01: And dramatically improves the patient's long-term quality of life, I'd imagine.
- 5:54SPEAKER_00: Exactly.
- 5:55SPEAKER_00: But to achieve that, you cannot just suppress the symptom.
- 5:58SPEAKER_00: You have to alter the biological environment.
- 6:00SPEAKER_00: You have to, as you said, rewire the alarm system.
- 6:02SPEAKER_01: Aaron Powell And that brings us to the proposed solution in these materials, which is stem cells.
- 6:08SPEAKER_01: Now I have to push back here for a second.
- 6:09SPEAKER_00: Sure, okay.
- 6:10SPEAKER_01: Because when most people hear the phrase stem cells, they immediately picture these magical blank slate building blocks.
- 6:17SPEAKER_00: The magic fix.
- 6:18SPEAKER_00: Yeah.
- 6:18SPEAKER_01: The common perception is that you inject them and literally overnight they multiply and build you a brand new colon lining from scratch.
- 6:26SPEAKER_01: Trevor Burrus, Jr.
- 6:26SPEAKER_00: Which is a huge misconception.
- 6:28SPEAKER_01: Exactly.
- 6:29SPEAKER_01: Reading through the Cyronicell documentation, they make it very, very clear that this is not what is happening in this specific treatment.
- 6:35SPEAKER_00: Aaron Powell What's fascinating here is the sheer specificity of the science.
- 6:39SPEAKER_00: We are not talking about a generalized magic cell.
- 6:42SPEAKER_00: Right.
- 6:42SPEAKER_00: The materials from Cyrona cell specify the use of adult stem cells.
- 6:46SPEAKER_00: And to be highly precise, they use early passage WJMSCs.
- 6:51SPEAKER_01: Wait, hold on.
- 6:52SPEAKER_01: WJMSCs.
- 6:54SPEAKER_01: The WJ stands for Wharton's Jelly, right?
- 6:56SPEAKER_00: It does, yes.
- 6:56SPEAKER_01: I have to admit, Wharton's jelly sounds like something you'd buy at an artisanal bakery or something.
- 7:00SPEAKER_01: What exactly is that in a medical context?
- 7:02SPEAKER_00: It does sound like that, yeah.
- 7:04SPEAKER_00: But it is a highly specific biological term.
- 7:07SPEAKER_00: Wharton's jelly is the gelatinous substance found inside the umbilical cord.
- 7:11SPEAKER_00: It surrounds and protects the blood vessels within the cord.
- 7:15SPEAKER_00: And it turns out this jelly is incredibly rich in mesinchinal stem cells.
- 7:20SPEAKER_01: Which is what the MSC stands for.
- 7:22SPEAKER_00: Exactly.
- 7:22SPEAKER_00: These are multipotent adult stem cells.
- 7:25SPEAKER_00: The materials note that these specific cells are ethically sourced from the umbilical cords of healthy, full-term deliveries.
- 7:32SPEAKER_01: And they get explicit donor consent for that, right?
- 7:34SPEAKER_00: Yes.
- 7:35SPEAKER_00: Obtained with complete and explicit donor consent.
- 7:37SPEAKER_01: Okay, so they take the cord after a healthy birth, extract this Wharton's jelly, and isolate the mesenchymal stem cells.
- 7:44SPEAKER_01: But the sources also spend a lot of time emphasizing what they do not use.
- 7:48SPEAKER_00: Yes, that's a critical point.
- 7:50SPEAKER_01: Why the strong focus on avoiding pluripotent or embryonic stem cells?
- 7:54SPEAKER_01: Like, what does pluripotent even mean?
- 7:56SPEAKER_00: So pluripotent stem cells, which include embryonic stem cells, have the ability to divide and develop into literally any cell type in the entire human body.
- 8:05SPEAKER_01: Like bone, muscle, brain, anything.
- 8:07SPEAKER_00: Anything.
- 8:08SPEAKER_00: While that sounds incredibly powerful, it is also highly unpredictable in a clinical setting.
- 8:13SPEAKER_01: Unpredictable how?
- 8:15SPEAKER_00: If you put pluripotent cells into a living patient, they can sometimes grow out of control and form tumors called teratomas.
- 8:23SPEAKER_01: Oh wow.
- 8:24SPEAKER_01: That sounds dangerous.
- 8:26SPEAKER_00: It is a major safety risk.
- 8:28SPEAKER_00: By explicitly excluding those and relying entirely on mesenchymal stem cells from Wharton's jelly, the clinic is prioritizing a predictable safety profile.
- 8:38SPEAKER_01: Because the MSCs are different.
- 8:40SPEAKER_00: Right.
- 8:40SPEAKER_00: MSCs are mature, specialized, adult stem cells.
- 8:45SPEAKER_00: They already have a very specific job description in the human body.
- 8:48SPEAKER_01: Okay.
- 8:48SPEAKER_01: So if they aren't pluripotent, they aren't turning into new colon cells.
- 8:51SPEAKER_01: They aren't acting like literal bricks building a new colon wall.
- 8:55SPEAKER_00: No, they aren't.
- 8:56SPEAKER_01: If I'm understanding this right, they are more like the construction form in walking onto the chaotic job site of the gut.
- 9:02SPEAKER_01: I like that.
- 9:02SPEAKER_01: Right.
- 9:03SPEAKER_01: Like they aren't pouring concrete, they're walking around with blueprints, yelling at the hyperactive immune system workers to put down their sledgehammers and start cleaning up the debris.
- 9:11SPEAKER_00: That captures the mechanism beautifully.
- 9:13SPEAKER_00: In the scientific literature, this is known as the pericrane effect.
- 9:16SPEAKER_01: The pericrane effect, okay.
- 9:18SPEAKER_00: The stem cells themselves are acting as biological helpers and immunomodulators.
- 9:23SPEAKER_00: They do not instantly replace the bowel lining.
- 9:25SPEAKER_01: So what do they do when they get in there?
- 9:27SPEAKER_00: Instead, when they introduced into the body, they home in on the sites of intense inflammation.
- 9:32SPEAKER_00: Once they arrive at the colon, they interact directly with the local immune cells.
- 9:36SPEAKER_00: Okay.
- 9:37SPEAKER_00: They release biochemical signals that actively reduce the pro-inflammatory forces, basically telling the workers to drop the sledgehammers.
- 9:45SPEAKER_00: Right.
- 9:46SPEAKER_00: And simultaneously, they stimulate the body's own native anti-inflammatory and tissue repair pathways.
- 9:52SPEAKER_01: I really want to dig into the HW of that, though.
- 9:55SPEAKER_01: How are these stem cells actually communicating with an angry immune system?
- 9:59SPEAKER_01: I mean, they don't have mouths.
- 10:00SPEAKER_00: Right.
- 10:00SPEAKER_00: It's not verbal.
- 10:01SPEAKER_01: How do they physically pass those blueprints to the immune cells?
- 10:05SPEAKER_00: They do it through a remarkable communication system, which introduces a critical component highlighted in the Cirona cell protocols, exosomes.
- 10:13SPEAKER_01: Exosomes.
- 10:14SPEAKER_01: The sources describe these as like tiny messenger packets.
- 10:17SPEAKER_01: How does a packet actually alter the behavior of an immune cell?
- 10:21SPEAKER_00: Think of the physical structure of a cell.
- 10:23SPEAKER_00: Exosomes are microscopic lipid-bound vesicles.
- 10:26SPEAKER_01: So basically tiny bubbles of fat.
- 10:29SPEAKER_00: Essentially, yes.
- 10:30SPEAKER_00: Bubbles of fat that the stem cells continuously secrete into their environment.
- 10:34SPEAKER_00: But they are empty bubbles.
- 10:35SPEAKER_00: They are packed full of specific proteins, lipids, and messenger RNA.
- 10:40SPEAKER_01: Okay, so they have a payload.
- 10:41SPEAKER_00: Exactly.
- 10:42SPEAKER_00: When an exosome floats over to a hyperactive immune cell in the gut, its lipid outer layer physically fuses with the outer membrane of that immune cell.
- 10:51SPEAKER_00: Wow.
- 10:51SPEAKER_00: It then drops its payload of RNA and proteins directly inside.
- 10:55SPEAKER_00: That payload acts like a new line of code, essentially reprogramming the immune cell's behavior from attack and destroy to calm down and repair.
- 11:03SPEAKER_01: Okay.
- 11:03SPEAKER_01: So the stem cells are the foreman, and the exosomes are like the text messages or emails they are blasting out to the entire crew.
- 11:10SPEAKER_00: That's a great way to put it.
- 11:11SPEAKER_01: You're essentially flooding the diseased gut with millions of biological text messages telling the immune system to initiate mucosal healing.
- 11:19SPEAKER_00: Yes, precisely.
- 11:20SPEAKER_01: Now, if you're listening to this and you've been on prednisone for three years, struggling with constant flares, you're probably rolling your eyes right now thinking, yeah, right, a magical biological text message is gonna fix my gut.
- 11:31SPEAKER_00: Aaron Powell And that skepticism is totally warranted.
- 11:34SPEAKER_01: It is.
- 11:35SPEAKER_01: That skepticism is exactly why theory is never enough.
- 11:39SPEAKER_01: Human biology is incredibly messy.
- 11:41SPEAKER_01: I mean, I need to know what happens when these biological foremen are actually put to the test in a real human body.
- 11:47SPEAKER_00: And that demand for evidence is exactly where we must turn to the clinical data.
- 11:52SPEAKER_00: The provided sources rely heavily on peer-reviewed human trials.
- 11:56SPEAKER_01: To bridge the gap between theory and reality.
- 11:58SPEAKER_00: Exactly.
- 11:59SPEAKER_00: There are two specific studies cited that paint a very clear picture of what this looks like in practice.
- 12:04SPEAKER_01: Let's walk through those because the details really matter here.
- 12:07SPEAKER_01: The first one is a randomized controlled clinical trial out of the affiliated hospital of Qingdao University in China.
- 12:13SPEAKER_01: They took a group of patients suffering from moderate to severe ulcerative colitis.
- 12:18SPEAKER_01: One group received their standard baseline therapy plus infusions of these umbilical cord MSCs.
- 12:24SPEAKER_01: The control group received the standard baseline therapy plus a saline placebo.
- 12:30SPEAKER_00: Right.
- 12:30SPEAKER_00: And in the hierarchy of medical evidence, a randomized control trial, or RCT, is the gold standard because it eliminates so much bias.
- 12:40SPEAKER_01: Because they're comparing it to placebo.
- 12:42SPEAKER_00: Exactly.
- 12:42SPEAKER_00: The researchers weren't just asking patients how they felt, they were tracking hard clinical markers.
- 12:47SPEAKER_01: And what did they find?
- 12:49SPEAKER_00: The results published from this trial showed that the group receiving the WJMSCs experienced significantly improved clinical and endoscopic measures compared to the placebo group.
- 12:59SPEAKER_01: Meaning the doctors physically scoped these patients and saw that the mucosal lining was actually healing faster and more completely than the group that only had standard medication.
- 13:09SPEAKER_00: That is correct.
- 13:09SPEAKER_01: Plus, the paper highlighted that there were no severe adverse reactions during the follow-up period, which is a massive concern when you are introducing foreign biological material into a patient.
- 13:19SPEAKER_00: Safety is always the top priority.
- 13:21SPEAKER_01: But what about the really difficult cases?
- 13:23SPEAKER_01: You know, what about the people whose bodies just completely reject standard treatments?
- 13:28SPEAKER_00: That specific demographic is addressed in the second study we have, which comes from the People's Hospital of Zhengzhou University.
- 13:35SPEAKER_01: Okay.
- 13:36SPEAKER_00: This was a two-month study focused explicitly on adult patients who had demonstrated a poor response to traditional pharmacological drugs.
- 13:44SPEAKER_01: So they're really tough cases.
- 13:46SPEAKER_00: The toughest.
- 13:47SPEAKER_01: Yeah.
- 13:47SPEAKER_00: These are the patients who are often staring down the barrel of surgical intervention, having their colons physically removed.
- 13:53SPEAKER_01: Oh man.
- 13:54SPEAKER_00: The researchers administered intravenous umbilical cord MSCs to this group.
- 13:59SPEAKER_01: And what did the data show for these non-responders?
- 14:02SPEAKER_00: The study reported highly meaningful rates of clinical response and clinical remission.
- 14:06SPEAKER_01: Even in the stubborn cases.
- 14:07SPEAKER_00: Even in those cases, yes.
- 14:09SPEAKER_00: They observed reductions in endocopic scoring, meaning the visual damage to the colon was actually reversing.
- 14:14SPEAKER_00: Wow.
- 14:15SPEAKER_00: Furthermore, they tracked a steep decline in systemic blood markers linked to inflammation, such as C-reactive protein.
- 14:22SPEAKER_01: Okay, here's where it gets really interesting for me.
- 14:24SPEAKER_01: Looking at this data, you have clinical trials showing that these cells can calm inflammation, heal the mucosal lining, and help people who are failing standard therapies.
- 14:34SPEAKER_00: The data is very compelling.
- 14:35SPEAKER_01: It is.
- 14:36SPEAKER_01: But in the modern landscape of medical tourism, you have clinics popping up all over the world that would take this exact data, slap it on a billboard, and scream miracle cure for colitis.
- 14:47SPEAKER_00: Unfortunately, yes, they would.
- 14:48SPEAKER_01: But the messaging in the Cyrona cell materials is incredibly restrained.
- 14:52SPEAKER_01: Why is the clinic itself so careful to label this as an add-on and not a cure?
- 14:58SPEAKER_00: Because that level of restraint is the absolute hallmark of responsible ethical regenerative medicine.
- 15:04SPEAKER_01: Okay.
- 15:04SPEAKER_00: Stem cell therapy, regardless of how promising the data is, is not a guaranteed cure for ulcerative colitis.
- 15:10SPEAKER_00: Presenting it as a silver bullet is scientifically inaccurate.
- 15:14SPEAKER_01: And medically unethical, probably?
- 15:16SPEAKER_00: Very unethical.
- 15:17SPEAKER_00: Autoimmune diseases are complex, multi-systemic conditions.
- 15:20SPEAKER_00: Cirenocell positions their therapy strictly as an adjunctive supportive option.
- 15:25SPEAKER_01: So setting realistic expectations.
- 15:27SPEAKER_00: Yes.
- 15:27SPEAKER_00: Exactly.
- 15:28SPEAKER_00: The realistic clinical goal is to achieve fewer flares, establish better symptom control, and potentially reduce a patient's long-term dependence on heavy steroids.
- 15:39SPEAKER_01: They are essentially saying we are a powerful tool in your toolbox, but we aren't throwing away the rest of the tools.
- 15:46SPEAKER_00: That's a perfect summary.
- 15:47SPEAKER_01: It's designed to work collaboratively with your current gastroenterologist, not to undermine them.
- 15:53SPEAKER_00: And that is a critical distinction for any patient navigating this space.
- 15:57SPEAKER_00: True medical experts coordinate with a patient's existing specialist.
- 16:01SPEAKER_00: Right.
- 16:01SPEAKER_00: If a listener ever encounters a clinic that tells them to fire their primary GI doctor, abandon all their standard medications overnight, and rely solely on a stem cell infusion because it's a miracle cure.
- 16:13SPEAKER_01: Run away.
- 16:14SPEAKER_00: They need to walk out the door immediately.
- 16:16SPEAKER_01: Which brings us to the physical reality of getting this treatment.
- 16:19SPEAKER_01: Let's look at the operational side of Sarona cell itself.
- 16:22SPEAKER_00: Sure.
- 16:22SPEAKER_01: According to the materials, they are based in Kuala Lumpur, Malaysia.
- 16:26SPEAKER_01: They serve a local population, but they also have a significant international reach.
- 16:30SPEAKER_00: Right, frequently drawing patients from Australia, the Middle East, and beyond.
- 16:34SPEAKER_01: I actually looked up the name Sirona while reading through this.
- 16:36SPEAKER_01: Apparently, she's an ancient Celtic goddess of health, healing, and protection.
- 16:41SPEAKER_00: Oh, that's interesting.
- 16:42SPEAKER_01: Which is a nice thematic touch, but honestly, if I'm flying to Malaysia to get an IV of biological material, I care a lot less about Celtic mythology and a whole lot more about lab standards.
- 16:54SPEAKER_00: And that is exactly where the focus of their clinical materials lies.
- 16:58SPEAKER_00: The contrast between the mythological name and their operational reality is stark.
- 17:03SPEAKER_00: Oh so their day-to-day protocols are governed by rigid international laboratory standards.
- 17:08SPEAKER_00: They operate their facilities under BSL II standards.
- 17:11SPEAKER_01: Okay, translate that alphabet suit for me.
- 17:13SPEAKER_01: What does BSL2 actually mean for the patient sitting in the chair?
- 17:17SPEAKER_00: Well, BSL2 stands for Biosafety Level 2.
- 17:19SPEAKER_00: It dictates strict environmental controls, specialized ventilation, and rigorous handling protocols.
- 17:25SPEAKER_01: Keep things clean.
- 17:26SPEAKER_00: To ensure that biological samples cannot be contaminated by outside pathogens.
- 17:31SPEAKER_00: Furthermore, they utilize CGMP current good manufacturing practice and ISO 9001 certified quality management systems.
- 17:41SPEAKER_00: In practical terms, this means that every single batch of Wharton's jelly stem cells goes through exhaustive, documented testing.
- 17:50SPEAKER_01: Testing for what specifically?
- 17:52SPEAKER_00: They test for cellular identity, ensuring they're actually MSCs.
- 17:56SPEAKER_00: They test for sterility, ensuring there are no bacteria or fungi.
- 18:00SPEAKER_00: Crucial.
- 18:01SPEAKER_00: And they test for viability, ensuring the cells are actually alive and active before they ever come near a patient's bloodstream.
- 18:07SPEAKER_01: Because if you have poor manufacturing, you could end up injecting dead cells or clumped cells or contaminated cells.
- 18:13SPEAKER_00: Which would be disastrous.
- 18:14SPEAKER_01: Right.
- 18:14SPEAKER_01: It could trigger a massive dangerous immune response, which is the exact opposite of what a UC patient needs.
- 18:21SPEAKER_00: Exactly.
- 18:22SPEAKER_01: Another thing that stood out in their protocol is the team structure.
- 18:25SPEAKER_01: It isn't just like one rogue doctor running a stem cell mill.
- 18:28SPEAKER_01: No, not at all.
- 18:29SPEAKER_01: The clinic utilizes a multidisciplinary team.
- 18:32SPEAKER_01: The sources list physicians with backgrounds in internal medicine, neurology, rehabilitation, and even sports medicine.
- 18:38SPEAKER_00: Which surprises a lot of people.
- 18:40SPEAKER_01: It surprised me.
- 18:41SPEAKER_01: I mean, if I have a gut disease, why do I need a sports medicine or rehab doctor involved in my care?
- 18:46SPEAKER_00: This raises an important point about the systemic nature of autoimmune disease.
- 18:50SPEAKER_00: Ulcerative colitis doesn't just stay in the gut, it affects the whole body.
- 18:54SPEAKER_00: Yes.
- 18:55SPEAKER_00: Chronic, body-wide inflammation severely impacts your joint health, your energy levels, your muscle mass, and your neurological well-being.
- 19:04SPEAKER_01: Oh, wow.
- 19:05SPEAKER_01: I didn't even think about the neurological impact.
- 19:07SPEAKER_00: It's significant.
- 19:08SPEAKER_00: A multidisciplinary team evaluates the entire patient, not just their colon.
- 19:14SPEAKER_00: They can provide transparent, holistic advice on whether this systemic therapy is appropriate and how it might impact the patient's overall physical rehabilitation.
- 19:23SPEAKER_01: Let's walk through the actual patient journey then, because this isn't a scenario where you just book a flight online, walk in, and get an IV.
- 19:30SPEAKER_00: No, it's very structured.
- 19:31SPEAKER_01: Right.
- 19:31SPEAKER_01: It's a highly structured pathway that starts with a rigorous medical evaluation.
- 19:36SPEAKER_01: In fact, they offer a free initial review of a patient's medical reports and current medication lists just to determine if they are even a viable candidate.
- 19:44SPEAKER_00: Which serves as a vital clinical gatekeeping mechanism.
- 19:48SPEAKER_00: A responsible clinic is actively looking for medical reasons not to treat you to ensure patient safety.
- 19:54SPEAKER_01: That makes sense.
- 19:55SPEAKER_00: The provided materials explicitly lists severe exclusions.
- 20:00SPEAKER_00: This therapy is absolutely not administered to individuals with active systemic infections, uncontrolled severe medical problems, or any history of cancer.
- 20:10SPEAKER_01: So a comprehensive medical review is the mandatory first step.
- 20:13SPEAKER_00: Absolutely mandatory.
- 20:14SPEAKER_01: Assuming a patient passes that evaluation and is deemed a safe candidate, step two is the stem cell preparation phase.
- 20:21SPEAKER_01: This is where those strict CGMP lab standards come into play, with the laboratory testing the specific batch for purity and strength.
- 20:29SPEAKER_01: Right.
- 20:29SPEAKER_01: And then comes step three, the actual administration.
- 20:31SPEAKER_01: I think a lot of people picture something highly invasive, maybe injecting cells directly into the damaged colon wall, but how is it actually delivered?
- 20:38SPEAKER_00: The administration is surprisingly minimally invasive, which is a significant relief for patients.
- 20:43SPEAKER_00: I'm bad.
- 20:44SPEAKER_00: The standard protocol does not involve open bowel surgery or direct intestinal injections.
- 20:49SPEAKER_00: The WJMSCs and exosomes are administered slowly through a standard intravenous drip.
- 20:56SPEAKER_01: Oh, just an IV.
- 20:57SPEAKER_00: Just an IV.
- 20:58SPEAKER_00: You're essentially sitting comfortably in a treatment chair while these biological messengers are introduced directly into your bloodstream.
- 21:06SPEAKER_01: And because they are introduced systemically, they utilize their natural homing mechanisms to travel through the bloodstream, locate the chemical signals of inflammation in the gut, and set up shop to begin communicating with the immune system.
- 21:18SPEAKER_00: That's exactly how it works.
- 21:20SPEAKER_01: Finally, step four is the monitoring and follow-up phase.
- 21:23SPEAKER_01: The clinic tracks the patient's symptom progression, monitors those crucial inflammatory blood markers, and adjusts the overall management plan.
- 21:31SPEAKER_00: To ensure the regenerative therapy is integrating smoothly with the patient's standard gastroenterology care.
- 21:37SPEAKER_01: Right.
- 21:37SPEAKER_00: If we step back and synthesize all of this information from the cyanocell materials, what we are really observing is the maturation of an entire medical field.
- 21:46SPEAKER_01: It's really growing up.
- 21:47SPEAKER_00: It is.
- 21:48SPEAKER_00: Regenerative medicine for complex conditions like ulcerative colitis is firmly moving out of the miracle cure era.
- 21:55SPEAKER_01: Thank goodness.
- 21:56SPEAKER_00: By harnessing ethically sourced WJMSCs and leveraging Their excessomess, clinics that strictly adhere to ISO and CGMP standards, are offering a highly sophisticated, medically supervised adjunct to traditional care.
- 22:10SPEAKER_01: They are leveraging the body's own communication networks.
- 22:14SPEAKER_00: Exactly.
- 22:14SPEAKER_01: And honestly, even if you do not suffer from ulcerative colitis or any autoimmune disease for that matter, this science still matters to you.
- 22:22SPEAKER_00: It really does.
- 22:23SPEAKER_01: It represents a massive paradigm shift in how human beings approach chronic illness.
- 22:28SPEAKER_01: For decades, modern medicine's primary strategy has been suppression.
- 22:32SPEAKER_00: Right.
- 22:32SPEAKER_00: Symptom management.
- 22:33SPEAKER_01: Like putting a heavy bucket under a leaky roof or throwing a blanket over a blaring car alarm.
- 22:39SPEAKER_01: We have relied on blunt chemical interventions.
- 22:41SPEAKER_00: Which have their place, but.
- 22:42SPEAKER_01: But now we're learning the actual language of the cells.
- 22:45SPEAKER_01: We're learning how to actively communicate with the body's immune system, sending precise biological instructions to stop the destruction and promote genuine healing from the inside out.
- 22:54SPEAKER_00: It's incredible.
- 22:55SPEAKER_01: We are finally figuring out how to rewire the alarm system.
- 22:59SPEAKER_00: It's the transition from purely pharmacological suppression to biological conversation.
- 23:04SPEAKER_00: We are giving the body the blueprints it needs to repair its own infrastructure.
- 23:09SPEAKER_01: And that leaves me with a final thought I want you to mull over as we wrap up this deep dive.
- 23:14SPEAKER_01: If adult stem cells and their exosome messengers can essentially talk a hyperactive, destructive immune system out of attacking the gut, what other chronic, deeply inflammatory diseases are we currently bombarding with heavy drugs that might just need the right biological whisper to heal themselves?
- 23:31SPEAKER_01: Think about that.